Literature DB >> 23398538

New advances in the diagnosis and treatment of POEMS syndrome.

Jian Li1, Dao-bin Zhou.   

Abstract

POEMS syndrome is a clonal plasma cell disease characterized by polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes. Significant advances have been made in the diagnosis and treatment of POEMS syndrome over the last decade. Herein, the diagnostic criteria and characteristic features are reviewed, focusing the role of characteristic features in early diagnoses. Autologous peripheral blood stem cell transplantation has become the first-line treatment for younger patients with normal organ function. Autologous transplantation has resulted in a high response rate and durable remission. Moreover, transplantation-related morbidity and mortality has been significantly reduced over the past 5 years. Induction therapy before transplantation may improve the harvest of stem cells and decrease transplantation-related morbidity. Melphalan and dexamethasone is an effective and well-tolerated treatment for older patients or those with organ dysfunction. Novel agents may also offer benefits to patients with a poor performance status or renal dysfunction, and transform transplantation eligibility.
© 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23398538     DOI: 10.1111/bjh.12236

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  32 in total

1.  POEMS syndrome: complex factors contributing to a delayed diagnosis.

Authors:  Rebecca Caroline Robey; Craig Campus; Beverly Ringuette; Mark Shumate
Journal:  BMJ Case Rep       Date:  2015-11-30

2.  Computed tomography assessment of bone lesions in patients with POEMS syndrome.

Authors:  K Glazebrook; Francis L Guerra Bonilla; Adam Johnson; S Leng; A Dispenzieri
Journal:  Eur Radiol       Date:  2014-09-25       Impact factor: 5.315

3.  Markedly elevated serum total N-terminal propeptide of type I collagen is a novel marker for the diagnosis and follow up of patients with POEMS syndrome.

Authors:  Chen Wang; Ying-Lei Zhou; Hao Cai; Xin-Qi Cheng; Wei Zhang; Wen-Ying Kang; Xu-Zhen Qin; Ming-Hui Duan; Hui-Juan Han; Xin-Xin Cao; Dao-Bin Zhou; Jian Li
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

Review 4.  Multicentric Castleman disease: Where are we now?

Authors:  Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2016-05-16       Impact factor: 3.464

5.  Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome.

Authors:  K Patel; M Nusrat; N Shah; Q Bashir; S Parmar; J Shah; S Thomas; D Weber; R Z Orlowski; R Champlin; M H Qazilbash
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

6.  Long-Term Therapy with Lenalidomide in a Patient with POEMS Syndrome.

Authors:  Benjamin F Chu; Arwa Shana'ah; Craig C Hofmeister; Don M Benson; Megan Sell; Jill Tucker; Flavia Pichiorri; Yvonne A Efebera
Journal:  Eur J Case Rep Intern Med       Date:  2014

7.  Castleman disease variant of POEMS syndrome complicated with multiple cerebral infarction: a rare case report and review of literature.

Authors:  Hang Yu; Fang Yao; Yue Li; Jian Li; Quan-Cai Cui
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

8.  Imaging findings in 22 cases of Schnitzler syndrome: characteristic para-articular osteosclerosis, and the "hot knees" sign differential diagnosis.

Authors:  Blake D Niederhauser; David Dingli; Robert A Kyle; Michael D Ringler
Journal:  Skeletal Radiol       Date:  2014-03-21       Impact factor: 2.199

9.  Multimodal imaging and clinical characteristics of bone lesions in POEMS syndrome.

Authors:  Xiao-Feng Shi; Shu-Dong Hu; Jun-Min Li; Xian-Fu Luo; Zhang-Biao Long; Yan Zhu; Xiao-Dong Xi
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 10.  [Polyglandular autoimmune syndromes : An overview].

Authors:  P Komminoth
Journal:  Pathologe       Date:  2016-05       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.